All data are based on the daily closing price as of July 17, 2024
h

HLB Life Science

067630.KQ
8.24 USD
0.05
+0.61%

Overview

Last close
8.24 usd
Market cap
386.20M usd
52 week high
18.14 usd
52 week low
5.90 usd
Target price
N/A usd

Valuation

P/E
N/A
Forward P/E
N/A
Price/Sales
17.1392
Price/Book Value
7.5395
Enterprise Value
1.33B usd
EV/Revenue
18.653
EV/EBITDA
80.0154

Key financials

Revenue TTM
63.60M usd
Gross Profit TTM
-4.11M usd
EBITDA TTM
-13.33M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
467.60M usd
Net debt
86.15M usd

About

HLB Life Science Co., Ltd. engages in the wholesaling and distribution of pharmaceuticals in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, esophageal cancer, thyroid cancer, mesothelioma, and neuroendocrine tumors; Seclidemstat, a novel epigenetic oral small molecule for target therapy to normalize gene expression and suppress tumor growth in various solid tumors, such as lung, breast, and prostate cancer; and Tegavivint, inhibitor of the Wnt/ß-catenin for the treatment of desmoid tumors, acute myeloid leukemia, osteosarcoma, and a range of solid tumor types. In addition, the company develops LifeLiver, an extracorporeal bioartificial liver system; HepaStem, a heterologous human adult liver-derived progenitor cell therapy; and HLBLS-200, a biocompatible polysaccharide-based powders that forms adhesive hemostasis upon contact with blood. Further, it is involved in the waste heat recovery, cogeneration power generation, facility installation, solar energy, photovoltaic power generation, bioenergy, geothermal energy, waste energy, wind power, and fuel cell businesses. The company also undertakes energy efficiency projects; and builds heating/heating system improvement projects. The company was formerly known as Energy Solutions Co., Ltd. and changed its name to HLB Life Science Co.,Ltd. in December 2015. HLB Life Science Co.,Ltd. was founded in 1998 and is headquartered in Hwaseong, South Korea.
  • Symbol
    067630.KQ
  • Exchange
    KQ
  • Isin
    KR7067630004
  • Country
    South Korea
  • Sector
    Healthcare
  • Industry
    Pharmaceuticals
  • CEO
    Sung-Bo Sim
  • Headquarter
    Hwaseong-si
  • Web site
    https://www.hlb-ls.com
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top